tacrolimus and monoethylglycinexylidide

tacrolimus has been researched along with monoethylglycinexylidide* in 2 studies

Trials

1 trial(s) available for tacrolimus and monoethylglycinexylidide

ArticleYear
Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine.
    Transplantation proceedings, 1995, Volume: 27, Issue:1

    Topics: Adolescent; Adult; Antilymphocyte Serum; Apolipoprotein A-I; Apolipoproteins B; Azathioprine; Bilirubin; Cholesterol; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Europe; Humans; Lidocaine; Liver Function Tests; Liver Transplantation; Methylprednisolone; Middle Aged; Prednisolone; Tacrolimus; Time Factors

1995

Other Studies

1 other study(ies) available for tacrolimus and monoethylglycinexylidide

ArticleYear
Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients.
    Hepatology (Baltimore, Md.), 1994, Volume: 20, Issue:2

    We have investigated the importance of cytochrome P-450IIIA enzyme activity in influencing dosage of the immunosuppressive drugs FK 506 and cyclosporine after liver transplantation. Cytochrome P-450IIIA enzyme activity in vivo was measured 1 yr postoperatively in 37 stable orthotopic liver graft recipients (21 receiving FK 506 and 16 given cyclosporine) by the erythromycin breath test and the production of monoethylglycinexylidide from lignocaine. A strong correlation existed between FK 506 dose and erythromycin breath test results (r = 0.583, p < 0.007), but no corresponding relationship with monoethylglycinexylidide production was observed. The FK 506 dose (14 to 196 micrograms/kg/day) also correlated closely with circulating predose levels of the drug in both plasma and blood (r = 0.538 and 0.731, p = 0.015 and < 0.001, respectively). Although no correlation existed between cyclosporine dose (0.254 to 0.494 mg/kg/day) and trough blood levels, a relationship was demonstrated when erythromycin breath test results were included in the derived equation: Drug dose/cytochrome P-450IIIA activity alpha drug level (p = 0.011 vs. 0.175 without erythromycin breath test). A corresponding enhancement was demonstrated with erythromycin breath test results to relate FK 506 dose and plasma levels (p = 0.006 versus 0.015 without erythromycin breath test results), although breath test results and FK 506 levels were highly discordant (p > 0.8). The use of monoethylglycinexylidide test results as an alternative measure of cytochrome P-450IIIA activity provided no comparable increase in correlation for FK 506 or cyclosporine.(ABSTRACT TRUNCATED AT 250 WORDS)

    Topics: Aryl Hydrocarbon Hydroxylases; Breath Tests; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; Female; Humans; Lidocaine; Liver Transplantation; Male; Oxidoreductases, N-Demethylating; Predictive Value of Tests; Regression Analysis; Tacrolimus

1994